Related Experiment Video
Updated: Apr 11, 2026

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature
O M Dekkers1, V Ehrenstein2, M Bengtsen2
1Department of Clinical EpidemiologyAarhus University Hospital, Aarhus, Denmark, Section of EndocrinologyDepartments of MedicineClinical EpidemiologyLeiden University Medical Center, Leiden, The NetherlandsDepartment of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus, Denmark Department of Clinical EpidemiologyAarhus University Hospital, Aarhus, Denmark, Section of EndocrinologyDepartments of MedicineClinical EpidemiologyLeiden University Medical Center, Leiden, The NetherlandsDepartment of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus, Denmark Department of Clinical EpidemiologyAarhus University Hospital, Aarhus, Denmark, Section of EndocrinologyDepartments of MedicineClinical EpidemiologyLeiden University Medical Center, Leiden, The NetherlandsDepartment of Endocrinology and Internal MedicineAarhus University Hospital, Aarhus, Denmark.
Objective:
To enhance the precision of the risk estimate for breast cancer in hyperprolactinemia patients by collecting more data and pooling our results with available data from former studies in a meta-analysis.
Design:
Population-based cohort study and meta-analysis of the literature.
Methods:
Using nationwide registries, we identified all patients with a first-time diagnosis of hyperprolactinemia during 1994-2012 including those with a new breast cancer diagnoses after the start of follow-up. We calculated standardised incidence ratios (SIRs) as a measure of relative risk (RR) using national cancer incidence rates. We performed a meta-analysis, combining data from our study with data in the existing literature.
Results:
We identified 2457 patients with hyperprolactinemia and 20 breast cancer cases during 19,411 person-years of follow-up, yielding a SIR of 0.99 (95% CI 0.60-1.52). Data from two additional cohort studies were retrieved and analyzed. When the three risk estimates were pooled, the combined RR was 1.04 (95% CI 0.75-1.43).
Conclusions:
We found no increased risk of breast cancer among patients with hyperprolactinemia.
Related Concept Videos
Disorders of the Female Reproductive System
Drug Toxicity: Risk factors
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Mitral Valve Prolapse III: Nursing Management

